Oncoinvent appoints Dr. Ramzi Amri as new CFO Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective…
Galapagos stock tumbles after company decides to wind down cell therapy unit By Investing.com Galapagos stock tumbles after company decides to wind down cell therapy unit…
Galapagos: Eine Aufspaltung soll das Unternehmen endlich aus dem Niemandsland führen Galapagos musste im August 2020 einen herben Rückschlag hinnehmen und war seitdem weitestgehend von der Bildfläche verschwunden. Das belgische Biopharmaunternehmen…
Galapagos receives transparency notification and 13D filing from Tang Capital Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification…
Galapagos downgraded by Barclays, PT cut to €22 By Investing.com Galapagos downgraded by Barclays, PT cut to €22…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing…
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging…